Bladder Carcinoma (Urothelial Cancer)

    Actionable Target Abnormality Prevalence (%) Clinical Experience with Targeted Agent
    PD-1/PD-L1 Expression not needed for activity Variable For second line, platinum failures:
    Pembrolizumab (PD-1 inhibitor) (FDA approved):
    • Phase 3: RR 21.1%, mOS 10.3 mo (1)
    Nivolumab (PD-1 inhibitor) (FDA approved):
    • Phase 2: RR 19.6%, mOS 8.7 mo (2)
    Atezolizumab (PD-L1 inhibitor) (FDA approved):
    • Phase 2: RR 15%, mOS 7.9 mo (3)
    FGFR3 Mutation 20 BGJ398 (FGFR3 inhibitor):
    • Phase 2: RR 36% (9/25 with FGFR3 mutation/translocation) (4)
    Erdafitinib (FGFR3 inhibitor):
    • Phase 1/2: RR 43.5% (10/23 with ion/translocation, continuous dose), 36% (4/11 with FGFR3 mutation/translocation, intermittent dose) (5)
    Other topics in Targets by Organ Site